Posted on November 26, 2018

The control of blood sugar levels in patients with diabetes remains suboptimal, with 1 in 2 patients on treatment for diabetes not reaching their glycemic goals.

With the aim of addressing this unmet need of patients, Sanofi, under the patronage of the Qatar Diabetes Association launched Toujeo® (insulin glargine U300), a next generation basal insulin, to improve the control of blood sugar in adults living with type 1 and type 2 diabetes. The launch was attended by the Ambassador of France to the State of Qatar. “Concern over hypoglycemia may cause people to modify their insulin dose. Around 4 in 10 patients with Type 2 Diabetes reduce their insulin dose after a mild hypoglycemic episode. Poor treatment adherence, persistence and intensity can result in sub-optimal control. With the new therapy, we are hoping to break the cycle of sub-optimal insulin use,” said Dr. Abdulla Al-Hamaq, Executive Director at the Qatar Diabetes Association, Qatar Foundation.

Toujeo® provides stable control that lasts a full 24 hours and beyond. It also provides the benefits of dosage flexibility (up to 3 hours) when needed. The new therapy has a neutral effect on cardiovascular conditions, ensuring long-term safety for patients with co-morbidities.

“Sanofi is proud of its strong and long heritage in diabetes and insulin therapies, including Lantus which has supported patients in the management of their diabetes for more than a decade. We are committed to bringing advanced therapies that aim to deliver better health outcomes for people with diabetes in Qatar. With the introduction of Toujeo, we offer effective alternative that will address some of the previously unmet needs of diabetes patients in the country,” said Lilya Ziad, Country Medical Chair.

The approval of Toujeo® is based on results from the EDITION clinical trial program, which comprised of a series of international studies evaluating the efficacy and safety of the drug in more than 3,500 adults from broad and diverse diabetes populations (type 1 and type 2).

At the end of the BRIGHT study, Toujeo demonstrated comparable blood sugar (HbA1c) control versus insulin degludec 100U/ml (-1.64% vs. -1.59%, respectively P-value <0.0001). During the first 12 weeks of therapy, a period when patients and physicians work to determine the most appropriate individual insulin dose, Toujeo reduced the rate of any time low blood sugar (Confirmed (≤3.9 mmol/l [≤70 mg/dl]hypoglycemia) events by 23 percent and the incidence of low blood sugar events by 26 percent, compared to insulin degludec 100U/ml (p<0.05). During the subsequent 12 weeks of the study (treatment period: 13-24 weeks), the two treatments showed comparable incidence and rate of low blood sugar events.